A Snapshot Of Neglected Disease Drug Development: Dengue Fever

24 Apr 2013

• By Alfred Romann

Neglected diseases are gaining a higher profile in Big Pharma drug development programs. Research on a vaccine for dengue fever has been ongoing for decades, and a few candidates could finally be nearing late-stage trials.

HONG KONG – Neglected diseases are gaining a higher profile in Big Pharma drug development programs. PharmAsia News offers a snapshot of the epidemiological status of some of the most prevalent neglected diseases, and where development stands to combat these overlooked diseases, starting with a look at dengue fever.

Every year, as the monsoon season kicks off in July, Pakistan braces itself for a surge in cases of dengue.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Four Chinese Firms Snag Global First-In-Class Approvals In China

11 Jul 2025

• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

10 Jul 2025

• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.